Pacira BioSciences, Inc.
Every calculator, already run for PCRX
Open the full toolkit →You have the numbers on PCRX. Get the argument.
A written report on which of these readings actually decide the outcome for Pacira BioSciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering PCRXAnalyst Price Target Disagreement for Pacira BioSciences, Inc.
Wall Street's bull case implies +54% from the current price; the bear case implies -7%. A 61% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for PCRX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also dev…
PCRX — frequently asked
Is PCRX a buy right now?
Wall Street's consensus rating on Pacira BioSciences, Inc. is none across 7 analysts, with a mean price target of $30.00 (+22% vs. the current $24.69). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is PCRX overvalued?
PCRX trades at 70.5x trailing earnings, against a DCF fair value of $96 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is PCRX's next earnings date?
Pacira BioSciences, Inc. is next scheduled to report earnings around Nov 5, 2026. A full PCRX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Pacira BioSciences, Inc.?
Analysts covering Pacira BioSciences, Inc. (PCRX) range from a bear-case target of $23.00 to a bull-case high of $38.00, with a mean consensus target of $30.00 across 7 analysts. The spread of $15.00 (61% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Pacira BioSciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Pacira BioSciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PCRX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Pacira BioSciences, Inc., in minutes. 3 free reports included with every account — no credit card required.